c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study

被引：0

作者：

Bar, J. ^{[1
]}

Baijal, S. ^{[2
]}

Luo, A. ^{[3
]}

Zhang, N. ^{[4
]}

Ratajczak, C. ^{[5
]}

Ansell, P. J. ^{[6
]}

Lu, S. ^{[7
]}

Camidge, D. R. ^{[8
]}

机构：

[1] Univ Hosp Birmingham, Sheba Med Ctr, Jusidman Canc Ctr, Ramat Gan, Israel

[2] NHS Fdn Trust, Med Oncol Dept, Birmingham, W Midlands, England

[3] AbbVie Inc, Oncol Stat, Chicago, IL USA

[4] AbbVie Inc, CDx Strategy & Precis Med, Chicago, IL USA

[5] AbbVie Inc, Oncol Early Dev, Chicago, IL USA

[6] AbbVie Inc, Precis Med Oncol, Chicago, IL USA

[7] Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China

[8] Univ Colorado, Med Oncol, Ctr Canc, Aurora, CO USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1434

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1379P

引用

页码：S866 / S866

页数：1

共 50 条

[31] A phase II study of the c-Met RTK inhibitor XL880 in patients (pts) with papillary renal-cell carcinoma (PRC)
Ross, R. W.
Stein, M.
Sarantopoulos, J.
Eisenberg, P.
Logan, T.
Srinivas, S.
Rosenberg, J.
Vaishampayan, U.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[32] Identification of a 7H-pyrrolo[2,3-d]pyrimidin derivatives as selective type II c-Met/Axl inhibitors with potent antitumor efficacy
Qin, Songhui
Xie, Lixin
Tang, Minghai
Ni, Hengfan
Yang, Tao
BIOORGANIC CHEMISTRY, 2025, 156
[33] Phase I/II study of 549076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma.
Hoang-Xuan, Khe
Hottinger, Andreas
Royer-Perron, Louis
Alentorn, Agusti
Savatovsky, Julien
De Micheli, Rita
Homicsko, Krisztian
Banquet, Sebastien
Pauly, Jeanne
Sudey, Isabelle
Tell, Roger
Therasse, Patrick
Barrie, Maryline
Campello, Chantal
Chinot, Olivier L.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[34] A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach
Pant, Shubham
Patel, Manish
Kurkjian, Carla
Hemphill, Brian
Flores, Maria
Thompson, Dana
Bendell, Johanna
CANCER INVESTIGATION, 2017, 35 (07) : 463 - 472
[35] Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer.
Liang, Han
Wang, Xiaona
Shang, Liang
Chen, Xiaodong
Cheng, Xiangdong
Li, Ziyu
Wei, Bo
Zheng, Zhichao
Li, Guoxin
Ji, Gang
Zhang, Zizhen
Tian, Yantao
Zhao, Qun
Yang, Lin
Liu, Heli
Chen, Hao
Liu, Yanliang
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS428 - TPS428
[36] Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study
Yang, Jin-Ji
Zhang, Yan
Wu, Lin
Hu, Jie
Wang, Zhe-Hai
Chen, Jing-Hua
Fan, Yun
Lin, Gen
Wang, Qi-Ming
Yao, Yu
Zhao, Jun
Chen, Yuan
Fang, Jian
Song, Yong
Zhang, Wei
Cheng, Ying
Guo, Ren-Hua
Li, Xing-Ya
Shi, He-Peng
Xue, Wei-Zhe
Han, Di
Zhang, Pei-Long
Wu, Yi-Long
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (31)
[37] Using modelling & simulation to integrate mouse PK-PD-efficacy with preliminary human PK data to inform the Phase II doses and schedule for the experimental c-Met inhibitor AZD6094 (Volitinib)
Jones, R.
Cheung, A.
Coleman, T.
Ballard, P.
D'Cruz, C.
Schuller, A.
Frigault, M.
Gu, Y.
Sai, Y.
Weiguo, S.
Ren, Y.
Qing, W.
Lindbom, L.
Petersson, K.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 125 - 126
[38] Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
Rimassa, Lorenza
Bozzarelli, Silvia
Pietrantonio, Filippo
Cordio, Stefano
Lonardi, Sara
Toppo, Laura
Zaniboni, Alberto
Bordonaro, Roberto
Di Bartolomeo, Maria
Tomasello, Gianluca
Dadduzio, Vincenzo
Tronconi, Maria Chiara
Piombo, Chiara
Giordano, Laura
Gloghini, Annunziata
Di Tommaso, Luca
Santoro, Armando
CLINICAL COLORECTAL CANCER, 2019, 18 (02) : 125 - +
[39] A phase II study of the c-Met inhibitor tivantinib (tiv) in combination with FOLFOX for the treatment of patients (pts) with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach.
Pant, Shubham
Patel, Manish R.
Kurkjian, Carla
Hemphill, Michael Brian
Flores, Maria Regina C.
Thompson, Dana Shelton
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[40] Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).
Waqar, Saiama Naheed
Redman, Mary Weber
Arnold, Susanne M.
Hirsch, Fred R.
Mack, Philip C.
Schwartz, Lawrence Howard
Gandara, David R.
Stinchcombe, Tom
Leighl, Natasha B.
Ramalingam, Suresh S.
Tanna, Saloni H.
Raddin, Ryan S.
Minichiello, Katherine
Kelly, Karen
Bradley, Jeffrey D.
Herbst, Roy S.
Papadimitrakopoulou, Vassiliki
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →